Biolase Q1 2024 Adj EPS $(0.36) Misses $(0.17) Estimate, Sales $10.131M Beat $9.996M Estimate
Portfolio Pulse from Benzinga Newsdesk
Biolase reported Q1 2024 adjusted EPS of $(0.36), missing the $(0.17) estimate, but its sales of $10.131M exceeded the $9.996M forecast. This represents a 3.21% decrease in sales compared to the same period last year.
May 13, 2024 | 8:08 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Biolase's Q1 2024 earnings report showed a significant miss on EPS estimates but a slight beat on sales forecasts, with a year-over-year decrease in sales.
The significant miss on the EPS estimate is likely to negatively impact investor sentiment and BIOL's stock price in the short term. Although the sales beat might offer some support, the overall negative earnings report and the year-over-year sales decrease are critical factors that could lead to a decrease in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100